Several studies have highlighted the potential role of matricellular glycoproteins in cancer progression (Chlenski and Cohn; Song et al. 2008; Wei et al. 2010 ). These diffusable extracellular matrix (ECM) elements modulate cellular dynamics by binding to transmembrane receptors, growth factors, cytokines, proteases, and the matrix scaffold. A prototypical matricellular glycoprotein implicated in suppression of ovarian cancer progression is SPARC (Secreted Protein, Acidic, Rich in Cysteine)/osteonectin.
SPARC expression in EOC cells is decreased compared to non-malignant ovarian epithelial cells (Mok et al. 1996) , which has been attributed to methylation-dependent epigenetic silencing of SPARC (Socha et al. 2009 ). Over-expression of SPARC in SKOV3 cells reduced cell proliferation and inhibited the ability of these cells to form tumors in nude mice (Mok et al. 1996) . Similarly, Said et al found that ectopic SPARC expression in these cells induced pleiotropic effects consistent with tumor suppressive activity, including reduction of lysophosphatidic acid (LPA)-induced cell proliferation, chemotaxis, and invasion (Said et al. 2007b) . SPARC also attenuated macrophage and -4 -mesothelial cell-induced production of IL-6, urokinase plasminogen activator, matrix metalloproteinases, and prostanoids (Said et al. 2008) , and suppressed anchorage dependent AKT and MAPK pathways in response to serum and epidermal growth factors (Said et al. 2007a ). Treatment of ovarian cancer cell lines in vitro with exogenous SPARC resulted in decreased proliferation and apoptosis (Bull Phelps et al. 2009; Said and Motamed 2005; Socha et al. 2009; Yiu et al. 2001) , indicating that these effects are likely mediated through extracellular effects of SPARC and that the findings can be extended to additional ovarian cancer cell lines. Altogether, these studies constitute compelling evidence for an antitumoral effect of SPARC in EOC.
In situ hybridization studies of patient samples revealed strong expression of SPARC transcripts confined to the reactive stroma of primary EOC tumors (Brown et al. 1999) . Subsequent studies have shown a similar upregulation of SPARC protein in reactive stroma in EOC (Paley et al. 2000) ; however, this upregulation was not observed in another immunohistochemical study (Yiu et al. 2001) . High levels of SPARC in tumor-associated stroma have been described for several solid tissue cancers including pancreatic, breast, and lung cancers. While the role of increased SPARC in these cancers is unclear, several studies in breast carcinoma indicate that increased stromal SPARC expression is associated with increased patient survival (Barth et al. 2005; Beck et al. 2008; Bergamaschi et al. 2008 (Abcam; rabbit polyclonal) or fibronectin (Abcam; rabbit polyclonal) followed by species-appropriate biotinylated secondary antibodies and finally peroxidise-conjugated streptavidin. Immunocomplexes were detected by 3',3'-diaminobenzidine treatment and counterstaining with hematoxylin. For immunofluorescent staining, endogenous autofluorescence was quenched using 0.2% sodium borohydride and sections were blocked in 5% normal serum. Sections were incubated with the endothelial-specific fluorescent conjugate isolectin IB4 (Sahagun et al. 1989) for four hours at room temperature (Invitrogen) followed by DAPI counterstaining. Photomicrographs were obtained at 200X magnification with an Olympus BX-61 fluorescent microscope.
Blood vessels were identified as single endothelial cells or cluster of cells with or without visible red blood cells. Microvessel area was measured relative to the total tissue area using integrated morphometry software (Metamorph). A minimum of 5 random fields of view were evaluated for each tissue (n=10 for each genotype).
Western Blotting
ID8 cells were cultured in serum-containing (10% FBS) or serum-free conditions. Cells were lysed using ice-cold RIPA buffer (25 mM Tris-HCl; pH 7.6, 150
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). Protein concentrations were determined by BCA reaction kit (Pierce) and equal amounts of total protein lysates were resolved on 10% SDS-PAGE gels and transferred to Immobilon polyvinylidene goat polyclonal. Peroxidase-conjugated secondary antibody was applied for one hour at room temperature. Samples were also probed using a GAPDH antibody (MAB374, Millipore) to enable loading of equal protein. Proteins were visualized with ECL chemiluminescence (GE Healthcare) and Konica X-ray film and the amount of SPARC protein was normalized against the intensity of the GAPDH signal.
Statistical Analysis
Survival data were plotted using the Kaplan-Meier method and differences between genotypes were determined using the Gehan-Wilcoxon test (Jager et al. 2008) .
Differences between genotypes with regards to presence of abdominal wall metastasis and petechial-like hemorrhages were analyzed by Fisher's exact test. Results for collagen wall thickness, endothelial immunofluorescence and immunohistochemical experiments were assessed with Student t test. Statistical analyses were performed using GraphPad Prism software. All statistical tests were two-sided and p> 0.05 was considered statistically significant.
Results

SPARC Increases Survival in an IP, but not OT model of EOC
To examine the effects of an absence of host-derived SPARC on ovarian tumor formation and cancer progression, ID8 cells were injected into the bursa surrounding the left ovary or into the peritoneal cavity of WT and Sparc -/-mice. Mice were injected with 1.0X10 6 ID8 cells in a 5 µl volume into the ovarian bursa or peritoneal cavity of Figure 1A ). In contrast, progression to a moribund state was not altered by SPARC expression in host animals when ID8 cells were administered OT ( Figure 1A ).
Ovarian SPARC has been implicated in regulating collagen fibrillogenesis and turnover, which could contribute to the differences observed in abdominal implant formation (Bradshaw et al. 2010) . We examined the fibrillar collagen content of abdominal wall (Table 1) .
SPARC Expression in OT Tumors
Ovarian tumors were only observed in mice injected OT with ID8 cells. Since prominently by accumulation of ascites. In contrast, no difference in survival was observed between these genotypes when ID8 cells were placed into the ovarian bursa.
These data suggests that a lack of SPARC within the peritoneum alters disease progression, whereas an absence of SPARC within the ovarian microenvironment has little or no significant impact. raising the possibility that the differences observed in peritoneal seeding in Sparc -/-mice are a result of more receptive stromal ECM rather than a direct effect of tumorassociated SPARC. Seeding of the peritoneum by EOC cells initially involves the attachment of cells to stromal collagen that is exposed near lymphatic ports referred to as milky spots (Cui et al. 2002; Khan et al. 2010) . The ensuing inflammatory environment results in retraction of the protective mesothelium, further exposing the adhesive collagen-rich stroma (Freedman et al. 2004) . SPARC has been shown to inhibit expression of macrophage chemoattractants and proinflammatory mediators (Said et al. 2008) , thus a peritoneal inflammatory response to IL8 injection would be enhanced in Sparc -/-mice. Moreover, it is increasingly evident that alterations in the ECM microenvironment has potent effects on metastasis (Egeblad et al. 2010) . Hence the lack of mature collagen fibrils and diminished expression of other ECM components such as collagen IV, laminin, and fibronectin (Said and Motamed 2005) in Sparc -/-mice may promote the observed phenotype of widespread attachment of ID8 cells rather than the formation of discrete lesions.
In contrast to the peritoneum, ovarian lesions from mice injected OT with ID8 cells did not exhibit differences between genotypes in content and maturity of collagen fibrils. Similarly, no difference in fibronectin content was evident in these ovarian tumors. Since fibronectin serves as a provisional matrix to promote collagen fibrillogenesis (Schwarzbauer 1991) , the abundance of fibronectin may overcome the impact of a lack of SPARC on collagen processing. In addition, ID8 cells produce significant amounts of SPARC which may augment fibronectin-mediated fibrillogenesis (Schwarzbauer 1991) . Given the marked activation of SPARC expression by the reactive stroma in human EOCs (Brown et al. 1999) , it was surprising that SPARC staining was not detected in the ovarian reactive stroma of WT as well as Sparc -/-mice.
The similarity in the collagen and fibronectin content of the ovarian tumor ECM between Sparc -/-and wild-type mice likely accounts for the lack of difference in disease progression when ID8 cells are injected OT. In light of the evidence that SPARC expression is activated in the ovarian reactive stroma associated with human EOC, the lack of stromal SPARC expression in the murine model limits the use of the OT model in addressing the role of SPARC in ovarian cancer progression. Moreover, in contrast to ID8 cells, human primary tumor EOC cells typically do not express SPARC (Brown et al. 1999; Paley et al. 2000) , due to hypermethylation of the SPARC promoter (Socha et al. 2009 ). and inhibits its interaction with its receptors, thereby exerting an anti-angiogenic effect (Kupprion et al. 1998) . Increased VEGF bioactivity could account for the increased vascular area, but since rapidly growing angiogenic vessels are tortuous and malformed, this increased area likely did not confer a growth advantage to ovarian tumors in the
While our data support a role for SPARC in inhibition of tumor progression after IP cancer cell injection, the mean difference in survival was less than that reported in previous studies. This survival difference may be attributed to variations in methodology between studies. As previously mentioned, the present study used a 50-fold lower number of cells than used in previous studies (Said and Motamed 2005; Said et al. 2007a; Said et al. 2007b; Said et al. 2008) . This was necessary to enable an equal number of cells injected into the ovarian bursa and peritoneal cavity. In addition, ascites volume was a principal factor contributing to our animals attaining a moribund state. In fact, the rate of ascites accumulation in mice injected IP with ID8 cells reported by Said and Motamed (Said and Motamed 2005) closely resembled the survival curves we report. VEGF plays a primary role in ascites production by increasing vascular permeability (Weis and Cheresh 2005) . Since SPARC inhibits VEGF activity, a more rapid accumulation of ascites would be expected in the absence of host-derived SPARC.
The observed increase in petechial-like hemorrhages in the peritoneum of Sparc -/-mice is also consistent with an excess of VEGF signaling. To our knowledge, our finding of peritoneal petechiae have not been previously reported in Sparc -/-mice; however, thrombocytopenia has been reported (Lehmann et al. 2007) . Since platelets play an important role in maintaining endothelial cell tight junctions, thrombocytopenia increases the occurrence of petechiae (Nachman 2008 
